To examine whether failure of AATx is due to elevated TNFα expression in GAMs, we examined expression of TNFα in CD68+ GAMs in GBM samples that were collected and processed prior to treatment with Bevacizumab and correlated the results with clinical outcome, using OS in Bevacizumab treatment as the end-point. Here, CD68 is linked to glioblastoma.